These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28847995)

  • 1. Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis.
    Abdulhadi B; Mulki R; Goyal A; Rangaswami J
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28847995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis.
    DiMaria C; Hanna W; Murone J; Reichart J
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31256051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
    Eek AK; Øie E; Granas AG
    Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
    Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
    Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
    Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
    Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient.
    Manno G; Novo G; Corrado E; Coppola G; Novo S
    J Cardiovasc Med (Hagerstown); 2019 Jun; 20(6):403-405. PubMed ID: 30762659
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
    Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA
    J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.